Argus lowered the firm’s price target on CVS Health to $80 from $100 but keeps a Buy rating on the shares. The analyst cites the company reporting Q1 earnings “well below expectations” as CVS is seeing higher-than-expected usage in the Medicare Advantage plans it sells in the Health Care Benefits business. Argus adds however that it still “sees value” in CVS Health shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS: